相似文献
1
Comment on "Dynamics of Serum CA19-9 in Patients Undergoing Pancreatic Cancer Resection".
Ann Surg Open. 2024 Jan 16;5(1):e376. doi: 10.1097/AS9.0000000000000376. eCollection 2024 Mar.
2
Dynamics of Serum CA19-9 in Patients Undergoing Pancreatic Cancer Resection.
Ann Surg. 2024 Mar 1;279(3):493-500. doi: 10.1097/SLA.0000000000005977. Epub 2023 Jul 3.
3
Diagnostic impact of postoperative CA19-9 dynamics on pancreatic cancer recurrence: a single-institution retrospective study.
Updates Surg. 2024 Apr;76(2):479-486. doi: 10.1007/s13304-024-01758-x. Epub 2024 Feb 13.
4
Prognostic significance of SUVmax and serum carbohydrate antigen 19-9 in pancreatic cancer.
World J Gastroenterol. 2014 May 21;20(19):5875-80. doi: 10.3748/wjg.v20.i19.5875.
5
Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma.
J Gastrointest Surg. 2012 May;16(5):977-85. doi: 10.1007/s11605-012-1859-9. Epub 2012 Mar 13.
6
New Cancer-Related Symptoms Predict Recurrence in CA19-9 Non-Expressers After Resection of Pancreatic Ductal Adenocarcinoma.
Am Surg. 2023 Nov;89(11):4469-4478. doi: 10.1177/00031348221117031. Epub 2022 Aug 3.
7
Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA19-9.
Pancreas. 1994 Nov;9(6):731-4. doi: 10.1097/00006676-199411000-00010.
8
Combination of Distance from Superior Mesenteric Artery and Serum CA19-9 as a Novel Prediction of Local Recurrence in Patients With Pancreatic Cancer Following Resection.
Anticancer Res. 2019 Mar;39(3):1469-1478. doi: 10.21873/anticanres.13264.
9
Tumor Size Combined With CA-19 Level Improves Prediction of Survival of Patients With Pancreatic Adenocarcinoma Undergoing Perioperative Chemotherapy and Resection.
Am Surg. 2024 Jun;90(6):1397-1405. doi: 10.1177/00031348241241738. Epub 2024 Mar 21.
10
Clinical Significance of Preoperative and Postoperative Serum CEA and Carbohydrate Antigen 19-9 Levels in Patients Undergoing Curative Resection of Locally Recurrent Rectal Cancer.
Dis Colon Rectum. 2023 Mar 1;66(3):392-400. doi: 10.1097/DCR.0000000000002655. Epub 2022 Dec 12.
本文引用的文献
1
The CA125 level postoperative change rule and its prognostic significance in patients with resectable pancreatic cancer.
BMC Cancer. 2023 Sep 6;23(1):832. doi: 10.1186/s12885-023-11346-8.
2
Dynamics of Serum CA19-9 in Patients Undergoing Pancreatic Cancer Resection.
Ann Surg. 2024 Mar 1;279(3):493-500. doi: 10.1097/SLA.0000000000005977. Epub 2023 Jul 3.
3
Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter.
Biochim Biophys Acta Rev Cancer. 2021 Apr;1875(2):188409. doi: 10.1016/j.bbcan.2020.188409. Epub 2020 Aug 19.
4
CA19-9 for detecting recurrence of pancreatic cancer.
Sci Rep. 2020 Jan 28;10(1):1332. doi: 10.1038/s41598-020-57930-x.
5
CA19-9 elevation as an indication to start salvage treatment in surveillance after pancreatic cancer resection.
Pancreatology. 2019 Mar;19(2):302-306. doi: 10.1016/j.pan.2019.01.023. Epub 2019 Feb 1.
6
Neoadjuvant and adjuvant chemotherapy in pancreatic cancer.
Langenbecks Arch Surg. 2018 Dec;403(8):917-932. doi: 10.1007/s00423-018-1724-8. Epub 2018 Nov 5.
7
New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer.
Pancreatology. 2018 Dec;18(8):971-976. doi: 10.1016/j.pan.2018.08.003. Epub 2018 Aug 9.
8
Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer.
Ann Surg. 2017 Apr;265(4):800-805. doi: 10.1097/SLA.0000000000001741.
9
The determinant factors of recurrence following resection for ductal pancreatic cancer.
JOP. 2007 Jan 9;8(1 Suppl):132-40.
10
Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population.
J Gastroenterol Hepatol. 2004 Feb;19(2):182-6. doi: 10.1111/j.1440-1746.2004.03219.x.
Zotero 插件